Navigation Links
Solazyme Selected for National Institute of Standards and Technology Award
Date:9/27/2007

$2 Million Grant to Support Development of Renewable Replacement for Light

Sweet Crude Oil

SOUTH SAN FRANCISCO, Calif., Sept. 27 /PRNewswire/ -- Solazyme, a bioscience company pioneering biofuels and health/wellness products from microalgae, has received a $2 million Advanced Technology Program Award from the National Institute of Standards and Technology to develop a biopetroleum derived from marine microorganisms.

Under the program, Solazyme will accelerate development of a renewable, domestically produced light sweet crude oil, or biopetroleum, which is fully compatible with the vast existing petroleum industry infrastructure that refines, distributes, and markets petroleum products for transportation, heating, power generation and petrochemical applications. Development of the biopetroleum technology requires efficient industrial scale bioproduction of pure, long-chain hydrocarbons. The ATP award will advance the achievement of major technical milestones toward commercialization of biopetroleum.

"We are pleased to receive external peer reviewed validation of our progress in developing a commercially viable biopetroleum," said Arthur Grossman, chief of genetics for Solazyme, Senior Scientist at the Carnegie Institution, Courtesy Professor at Stanford University and Darbaker prize recipient. "We look forward to advancing this project and adding additional technical expertise to our team as we continue to further the science and the future applications of algal-derived bioenergy."

Solazyme is currently developing biofuels and health/wellness products with microalgae and producing next generation biofuels at the semi-commercial scale. Biopetroleum complements Solazyme's biofuel portfolio, which also includes biodiesel, renewable diesel and renewable (bio)jet fuel and leverages Solazyme's unique expertise in the field of microalgae bioengineering.

"The Advanced Technology Program has historically funded the development of game-changing technologies and we are delighted to be in such esteemed company," added Harrison Dillon, chief executive officer of Solazyme. "The scientific strategy underlying our approach to create biopetroleum will leverage Solazyme's core strengths in the genetic manipulation of microalgae and potentially play a significant role in securing US energy independence."

About Solazyme:

Founded in 2003 and headquartered in South San Francisco, California, Solazyme is a leading biotechnology company focused on the engineering and optimization of algae for production of biofuels and health and wellness materials. For more information, please visit our website: http://www.solazyme.com.

For More Information Contact:

Jackie Kolek Ellen Snook

Peppercom Peppercom

212-931-6166 415-438-9821

jkolek@peppercom.com esnook@peppercom.com


'/>"/>
SOURCE Solazyme
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. San Diego firm selected for Madison Wi-Fi project
2. Milwaukee-based eFilm software selected by InSight Health, announces Workstation upgrade
3. Berbee Selected by Microsoft as Featured Speaker for New Product Launch
4. National Instruments DIAdem -- Complete Your Technical Data Management Framework with Powerful Off-line Analysis, Visualization, and Report Generation
5. Schneider National exec joins TrafficCast board
6. Olympics of biotechnology has international flavor
7. Wisconsin professors elected to National Academy of Sciences
8. CIO Leadership Series: Judy Lemke, Schneider National
9. National angel investment grew 11 percent in `06
10. National broadband policy: Lets get it right this time
11. National Academies induct five UW researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... BETHESDA, Md. , Jan. 18, 2017  Northwest ... company developing DCVax® personalized immune therapies for operable and ... Marnix Bosch , Chief Technical Officer of NW Bio, ... Thursday, January 19, 2017, at the Hyatt Regency Hotel ... Dr. Bosch will chair the session entitled "New Therapeutic ...
(Date:1/18/2017)... , January 18, 2017 According to a new ... Diagnosis, Neuroscience, Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, Academic and ... expected to reach USD 739.9 Million by 2021 from USD 557.1 Million in ... Reading ... MarketsandMarkets Logo ...
(Date:1/18/2017)... ... January 18, 2017 , ... Executive search firm Slone Partners ... commitment to the advancement of the clinical trials segment. Hosted in Miami, this ... trial planning and management. , As executive talent specialists in the industries ...
(Date:1/18/2017)... ... January 18, 2017 , ... MYOLYN, which creates medical technology ... a 510(k) to the FDA, requesting clearance of the MyoCycle Home and the ... technology. , The submission marks a major milestone for the technology startup. ...
Breaking Biology Technology:
(Date:1/4/2017)... LAS VEGAS , Jan. 4, 2017 /PRNewswire/ ... in performance biometric sensor technology, today announced the ... Benchmark™ sensor systems, the highly-accurate biometric sensor ... ® biometric technology, experience and expertise. The ... of Benchmark designed specifically for hearables, and Benchmark ...
(Date:12/20/2016)... Dec, 20, 2016   Valencell , the ... and STMicroelectronics (NYSE: STM), a global semiconductor ... applications, announced today the launch of a new, ... wearables that includes ST,s compact SensorTile ... biometric sensor system. Together, SensorTile and Benchmark ...
(Date:12/15/2016)... Canada and BADEN-BADEN, Germany , ... a leading global financial services provider, today announced an agreement ... passive behavioural biometrics, to join forces. The partnership will enable ... mitigation strategies in compliance with local data protection regulation. ... In order ...
Breaking Biology News(10 mins):